KojiSasakiMD

PubMed

• Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing ...
  Lewis F Nasr, Jayastu Senapati, Rebecca Garris, Farhad Ravandi, Nicholas J Short, Elias Jabbour, Nitin Jain, Fadi G Haddad, Ghayas C Issa, Koji Sasaki, Partow Kebriaei...> ;American Journal of Hematology. 2024 Apr 12
• Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
  Wei-Ying Jen, Wei Qiao, Farhad Ravandi, Koji Sasaki, Sanam Loghavi, Sa A Wang, Gautam Borthakur, Tapan M Kadia, Ghayas C Issa, Nicholas J Short, Musa Yilmaz, Naval G D...> ;British Journal of Haematology. 2024 Apr 11
• Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
  Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
• Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
  Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
• 1 citations
  Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
  Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
• The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in ...
  Fadi G Haddad, Koji Sasaki, Ghayas C Issa, Elias Jabbour, Hagop Kantarjian> ;American Journal of Hematology. 2024 Mar 28
• Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
  Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Kelly Sharon Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasak...> ;Blood Advances. 2024 Mar 21
• Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
  Ziyi Li, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Danielle Hammond, Sherry A Pierce, Kelly S Chien, Faustine Ong, Kunhwa Kim, Courtney D DiNardo, Koichi Tak...> ;Cancer Medicine. 2024 Mar 1
• Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib.
  Cedric Nasnas, Shilpa Paul, Caitlin Rausch, Fadi G Haddad, Koji Sasaki, Ghayas C Issa, Elias Jabbour, Hagop Kantarjian> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 29
• Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies.
  Garcia, M. B., Bofei Wang, Patrick K Reville, Mhd Yousuf Yassouf, Fatima Z Jelloul, Christopher Ly, Poonam N Desai, Zhe Wang, Pamella Borges, Ivo Veletic, Enes Dasdemi...> ;Nature Communications. 2024 Feb 28
• Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
  Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, Rashmi Kanagal-Shamanna, Danielle Hammond, Kelly Chien, Koji Sasaki, Elias Jabbour, Cour...> ;Leukemia. 2024 Feb 28
• Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center pha...
  Issa F Khouri, Kamal Alzahrani, Hagop Kantarjian, Denái R Milton, Alison M Gulbis, Koji Sasaki, Nitin Jain, Nicholas J Short, Tapan Kadia, May Daher, Hind Rafei, Jin S...> ;American Journal of Hematology. 2024 May 1
• BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
  Warren Fiskus, Jessica Piel, Michael P Collins, Murphy Hentemann, Branko Cuglievan, Christopher P Mill, Christine Birdwell, Kaberi Das, John A Davis, Hanxi Hou, Antrix...> ;Blood. 2024 Feb 16
• Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
  Ravandi, F., Pierce, S., Sasaki, K., Kadia, T., DiNardo, C., Yilmaz, M., Short, N., Jabbour, E., Patel, K., Loghavi, S., Borthakur, G., Kantarjian, H.> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 3
• 1 citations
  Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2...
  Bataller, A., Montalban-Bravo, G., Bazinet, A., Alvarado, Y., Chien, K., Venugopal, S., Ishizawa, J., Hammond, D., Swaminathan, M., Sasaki, K., Issa, G., Short, N., Ma...> ;The Lancet. Haematology. 2024 Mar 1
• Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
  Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S Chien...> ;Clinical Cancer Research. 2024 Apr 1
• Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
  Rivera, D., Cui, W., Gao, J., Peker, D., Zhang, Q., Dewar, R., Qiu, L., Konoplev, S., Hu, Z., Sasaki, K., Hu, A., E, S., Liu, M., Fang, H., Wang, W., Tang, G., Apperle...> ;Modern Pathology. 2024 Feb 1
• Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
  Birdwell, C., Fiskus, W., Kadia, T., Mill, C., Sasaki, K., Daver, N., DiNardo, C., Pemmaraju, N., Borthakur, G., Davis, J., Das, K., Sharma, S., Horrigan, S., Ruan, X....> ;Leukemia. 2024 Mar 1
• 3 citations
  Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes.
  Wurster, S., Jiang, Y., Lewis, R., Matsuo, T., Sasaki, K., Tarrand, J., Kontoyiannis, D.> ;The Journal of Antimicrobial Chemotherapy. 2024 Feb 1
• Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
  Jen, W., Rausch, C., Alvarado, Y., McCue, D., Ravandi, F., Sasaki, K., DiNardo, C., Kadia, T., Yilmaz, M., Borthakur, G., Kantarjian, H., McCue, D.> ;Leukemia & Lymphoma. 2024 Mar 1
• Early mortality after chemotherapy as a quality indicator-the leukemia perspective.
  Hagop Kantarjian, Mary Alma Welch, Koji Sasaki> ;Blood Cancer Journal. 2023 Dec 1
• Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes.
  Koji Sasaki> ;The Lancet. Haematology. 2023 Nov 1
• 2 citations
  Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
  Fadi G Haddad, Nicholas J Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Yesid Alvarado, Xuemei Wang, Lucia Masarova, Farhad Ravandi, Elias Jabbour, Jeffrey Jorgens...> ;Blood. 2024 Feb 1
• 2 citations
  Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, an...
  Koji Sasaki, Fadi G Haddad, Nicholas J Short, Nitin Jain, Ghayas Issa, Elias Jabbour, Hagop Kantarjian> ;Cancer. 2023 Dec 1
• 1 citations
  Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
  Danielle Hammond, Sanam Loghavi, Sa A Wang, Marina Y Konopleva, Tapan M Kadia, Naval G Daver, Maro Ohanian, Ghayas C Issa, Yesid Alvarado, Nicholas J Short, Koji Sasak...> ;Blood Cancer Journal. 2023 Sep 21
• Join now to see all